Company News_News_Shanghai Kechow Pharma, Inc.

中文

News

Location：Home/News/Company News

Company News

A Pride of Chinese Innovation! The First Innovative MEK Inhibitor Bringing New Hope to Colorectal Cancer Patients
2025-05-13
Original article by Yan Xiao | CPHI PharmaSources | March 12, 2025, 16:31, ShanghaiOn December 04, 2
Comparison of Structures of Small-Molecule Drugs Independently Developed in China in 2024 and Drugs Targeting the Same Sites
2025-01-03
Original article by Lao Yang666 | Talks on Pharmaceutical Chemistry January 01, 2025, 21:23, Shangha
Breaking News | Kechow Pharma's New Class 1 Innovative Drug Officially Included in China's New National Reimbursement Drug List, Benefiting More NRAS-mutant Advanced Melanoma Patients
2024-11-28
According to the announcement of the National Healthcare Security Administration of China on Novembe
Exciting News! The First Prescription of Kolupin® (Tunlametinib) Marks a New Era in Treating Advanced NRAS-Mutant Melanoma
2024-05-23
In March 2024, Kolupin® (Tunlametinib) was approved in China for use in patients with advanced NRAS-
Exciting News! First Domestically Developed MEK Inhibitor Kolupin (Tunlametinib) Receives NMPA Approval for Market Release
2024-03-15
The first worldwide MEK inhibitor approved for treating advanced NRAS-mutant melanoma.The first MEK
KeChow Pharma and Sinopharm Global Procurement Sign Strategic Cooperation Agreement
2024-01-24
On January 23, 2024, Shanghai Kechow Pharma Inc. (“KeChow Pharma”) and Sinopharm Global Procurement

1
2
3
4
>